# GoodRx Reports First Quarter 2026 Results
Canonical URL: https://biopharmsignal.com/news/GDRX/goodrx-reports-first-quarter-2026-results
Ticker: GDRX
Company: GoodRx
Source: GoodRx
Published: 2026-05-06 20:05 EST
Original Source URL: https://investors.goodrx.com
## Summary

Pharma Direct Revenue Increased 82% Year-Over-Year in the First Quarter Company Raises Full Year 2026 Revenue and Adjusted EBITDA Expectations SANTA MONICA, Calif. --(BUSINESS WIRE)--May 6, 2026-- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading

## Article Body
Pharma Direct Revenue Increased 82% Year-Over-Year in the First Quarter Company Raises Full Year 2026 Revenue and Adjusted EBITDA Expectations SANTA MONICA, Calif. --(BUSINESS WIRE)--May 6, 2026-- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading
## Recent Company News
- 2026-05-27 13:00 EST — [GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs](https://biopharmsignal.com/news/GDRX/goodrx-launches-goodrx-companion-a-new-subscription-designed-to-lower-everyday-healthcare-costs) — Source: GoodRx
- 2026-05-06 20:05 EST — [GoodRx Reports First Quarter 2026 Results](https://biopharmsignal.com/news/GDRX/goodrx-reports-first-quarter-2026-results) — Source: GoodRx
- 2026-05-01 12:10 EST — [GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients](https://biopharmsignal.com/news/GDRX/goodrx-expands-offerings-to-now-include-ozempicr-pill-for-type-2-diabetes-patients) — Source: GoodRx
- 2026-04-17 20:05 EST — [GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/GDRX/goodrx-announces-date-for-first-quarter-2026-earnings-release-and-conference-call) — Source: GoodRx
- 2026-04-15 13:00 EST — [GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price](https://biopharmsignal.com/news/GDRX/goodrx-now-offers-access-to-wegovyr-hd-at-399-per-month-self-pay-price) — Source: GoodRx
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)